Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma

Dilan A. Patel, Ragisha Gopalakrishnan, Brian G. Engelhardt, Evonne McArthur, Salyka Sengsayadeth, Katie A. Culos, Michael Byrne, Stacey Goodman, Bipin N. Savani, Wichai Chinratanalab, Madan Jagasia, Claudio A. Mosse, Robert F. Cornell, Adetola A. Kassim

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Modern combinations of therapies for multiple myeloma have led to improvement in survival outcomes with near 100% overall response rate and 25% complete response rates, particularly with autologous hematopoietic cell transplant (AHCT). Minimal residual disease (MRD) assessment with multiparameter flow cytometry is a valid prognostic biomarker for progression-free survival (PFS) and overall survival (OS). However, few data exist regarding whether MRD positivity or negativity will meaningfully influence treatment decisions. We evaluated 433 patients who received induction therapy, followed by AHCT. Participants had MRD assessment by multiparameter flow cytometry before and at days +100 and +365 following AHCT. They also received either lenalidomide, bortezomib, or no maintenance therapy following AHCT. Maintenance treatment with lenalidomide improved MRD negativity at day +365 compared to bortezomib (92.9% vs 41.6%, p = 0.01), or no maintenance therapy (92.9% vs 24.4%, p = 0.012). The median PFS for patients who were MRD negative at day + 365 was 42 vs 17.5 months (p < 0.001) and median OS was 80.6 vs 59 months (p = 0.02). Maintenance therapy following AHCT for multiple myeloma improves the depth of response as assessed by MRD.

Original languageEnglish
Pages (from-to)1137-1146
Number of pages10
JournalBone Marrow Transplantation
Volume55
Issue number6
DOIs
StatePublished - Jun 1 2020

Fingerprint

Dive into the research topics of 'Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma'. Together they form a unique fingerprint.

Cite this